GGrantIndex
← Search

Analytical Cytometry Core

$2,084P30FY2018CANIH

Beckman Research Institute/City Of Hope, Duarte CA

Investigators

Linked publications, trials & patents

Trial NCT07664670Trial NCT07664579Trial NCT07650656Trial NCT07628894Trial NCT07619599Trial NCT07612085Trial NCT07611370Trial NCT07608627Trial NCT07608458Trial NCT07608445Trial NCT07595874Trial NCT07590583Trial NCT07583810Trial NCT07583303Trial NCT07582172Trial NCT07582159Trial NCT07578077Trial NCT07578025Trial NCT07544992Trial NCT07365306Trial NCT07363408Trial NCT07293403Trial NCT07288034Trial NCT07278856Trial NCT07275216Trial NCT07271355Trial NCT07235501Trial NCT07226544Trial NCT07226102Trial NCT07225855Trial NCT07225738Trial NCT07220447Trial NCT07219147Trial NCT07218913Trial NCT07218718Trial NCT07218692Trial NCT07218510Trial NCT07210086Trial NCT07202247Trial NCT07184294Trial NCT07136493Trial NCT07133997Trial NCT07128680Trial NCT07126301Trial NCT07125729Trial NCT07042438Trial NCT07040982Trial NCT07037004Trial NCT07025564Trial NCT07025538Trial NCT07020533Trial NCT07003100Trial NCT06996119Trial NCT06985784Trial NCT06954831Trial NCT06922604Trial NCT06918431Trial NCT06910761Trial NCT06860815Trial NCT06859008Trial NCT06834126Trial NCT06815029Trial NCT06815003Trial NCT06780787Trial NCT06763341Trial NCT06763328Trial NCT06735690Trial NCT06735664Trial NCT06731894Trial NCT06675136Trial NCT06675123Trial NCT06672224Trial NCT06626256Trial NCT06625619Trial NCT06581211Trial NCT06580015Trial NCT06575725Trial NCT06575686Trial NCT06575296Trial NCT06572631Trial NCT06572618Trial NCT06572605Trial NCT06549478Trial NCT06543381Trial NCT06538389Trial NCT06500377Trial NCT06498973Trial NCT06454409Trial NCT06454383Trial NCT06453044Trial NCT06447987Trial NCT06440850Trial NCT06408220Trial NCT06399419Trial NCT06328621Trial NCT06287944Trial NCT06260033Trial NCT06249282Trial NCT06196008Trial NCT06195891

Abstract

Analytical Cytometry Core Shared Resource ABSTRACT To advance our understanding of cancer etiology and to develop improved therapeutic approaches, it is critical for researchers to have the ability to routinely analyze and isolate discrete cell types from complex heterogeneous populations. The Analytical Cytometry Core (ACC) fulfills this vital function for CC members by providing services to define and isolate discrete immune system cells and cancer cells based on cell surface markers, to quantify and isolate cells that express fluorescent markers, and to examine discrete cell growth states. The ACC provides flow cytometry analysis and sorting instrumentation (ten analyzers, four sorters) to support the research goals of the City of Hope Comprehensive Cancer Center (COHCCC). The ACC maintains several analysis instruments (BC Gallios, BC CyAn, BD C6, and two BD Fortessas) that enable varying degrees of parameter detection in the Furth building on the COH main campus. These instruments can be operated either by researchers or by core staff. A small particle analyzer (e.g., exosome and nanoparticle; NanoSight NS300) is also available at this location. Additional analyzers are available throughout the main campus and the City of Hope Biomedical Research Center (BC Gallios, two BD C6, BD Fortessa, and BD Fortessa X-20). Three high-parameter cell sorting instruments (BD Aria sorters), located on the main campus and the City of Hope Biomedical Research Center, are maintained and operated by core staff. An additional simple cell sorter (Bio- Rad S3), located on the main campus, is available for operation by individual researchers. Several additional instruments are on order with scheduled delivery in July 2017: a BD Fortessa X-20, a BD Aria Fusion sorter, and a state-of-the-art high-dimensional cytometer (BD FACSymphony). The core is directed by Dr. Jeremy Stark, a Professor in the Department of Cancer Genetics and Epigenetics, and supported by highly qualified staff that maintain and operate the equipment while also providing training to COHCCC researchers who wish to operate ACC instruments independently. Trained and authorized users have 24/7 access to the instrumentation, and core staff schedules are staggered to allow for an extended workday for core-assisted operation. Oversight is provided by an interdisciplinary faculty Advisory Committee, and user feedback through an annual survey. Over the past five years, the ACC was used by 142 unique investigators, including 94 CC members. Of the 94 CC members, 79 (84%) had peer-reviewed funding. Usage included members from all five Programs. Thus, the ACC provides accessible, cost-effective, and high quality flow cytometry services to support the research of the COHCCC.

View original record on NIH RePORTER →